Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.53 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577560 | 0.94 | HTR4 (0.53) | CCR3HTR4DRD3MEN1KMT2A | |
| SCHEMBL5577451 | 0.88 | SIGMAR1 (0.48) | MEN1KMT2ADRD2SIGMAR1 | |
| SCHEMBL5577575 | 0.88 | DRD3 (0.53) | CCR3HTR4DRD3MEN1KMT2A | |
| SCHEMBL5577694 | 0.86 | SIGMAR1 (0.51) | CCR3HTR4DRD3MEN1KMT2A | |
| SCHEMBL5577726 | 0.85 | SIGMAR1 (0.51) | DRD3KMT2APLA2G1BATG4BCHRM4 | |
| SCHEMBL5577884 | 0.85 | SIGMAR1 (0.47) | DRD3DRD2DRD4CHRM4SIGMAR1 | |
| SCHEMBL5577428 | 0.85 | SIGMAR1 (0.47) | MEN1KMT2ADRD4CHRM4SIGMAR1 | |
| SCHEMBL5577373 | 0.84 | SIGMAR1 (0.48) | HTR4CHRM4SIGMAR1 | |
| SCHEMBL5577515 | 0.84 | POLB (0.53) | CCR3DRD3MEN1KMT2ASIGMAR1 | |
| SCHEMBL5577829 | 0.83 | SIGMAR1 (0.51) | HTR4MEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | CCR3 120/4885HTR4 2137/4885DRD3 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.